Pharma BD Deal Intelligence
Chiron's communication frames TOBI as the gold standard for treating cystic fibrosis patients with Pseudomonas aeruginosa lung infections, already marketed in…
TOBI was generating approximately $86M in worldwide sales in the year preceding the Chiron acquisition, with Chiron subsequently partnering with Inhale…
Nebulized tobramycin (Tobi) became established as the inhaled standard-of-care for chronic Pseudomonas aeruginosa infection in cystic fibrosis, validating the…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Chiron agreed to pay $700M in cash for Seattle-based PathoGenesis. Deal added inhaled antibiotic TOBI (chronic CF lung infections) plus inhaled-antibiotic pipeline and ~275 staff. Anchored Chiron's anti-infectives franchise. Closed Sep 29, 2000.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Chiron Corporation / PathoGenesis Corporation (this deal) | 2000 | $700M | 75 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| bioMerieux SA / BioFire Diagnostics Inc. | 2013 | $485M | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2000 deals · Infectious Disease deals